Bimagrumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sporadic Inclusion Body Myositis
Conditions
Sporadic Inclusion Body Myositis
Trial Timeline
Nov 2, 2015 → Feb 13, 2017
NCT ID
NCT02573467About Bimagrumab + Placebo
Bimagrumab + Placebo is a phase 3 stage product being developed by Novartis for Sporadic Inclusion Body Myositis. The current trial status is completed. This product is registered under clinical trial identifier NCT02573467. Target conditions include Sporadic Inclusion Body Myositis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02573467 | Phase 3 | Completed |
| NCT02468674 | Phase 2 | Completed |
Competing Products
7 competing products in Sporadic Inclusion Body Myositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BYM338 (Bimagrumab) | Novartis | Phase 2/3 | 65 |
| BYM338/bimagrumab + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus | Novartis | Phase 2 | 52 |
| BYM338 + Placebo | Novartis | Phase 2 | 52 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN2477+REGN1033 + Matching placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |